Evidence map›Paper›PMID 41293419›Full record

ArticleFrontiers in cell and developmental biology2025

Deficiency for MicroRNA-582 does not impact dilated cardiomyopathy or heart failure induced by pressure overload

Simone Martini, Inka Dobberstein, Nesrin Schmiedel, Lucia Sophie Kilian, Jakob Christoph Voran, Frauke Senger, Ashraf Yusuf Rangrez, Derk Frank, Christian Kuhn, Norbert Frey

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Simone MartiniDepartment of Internal Medicine III, Cardiology and Critical Care, University Hospital Schleswig-Holstein, Kiel, Germany.
Inka DobbersteinDepartment of Internal Medicine III, Cardiology and Critical Care, University Hospital Schleswig-Holstein, Kiel, Germany.
Nesrin SchmiedelDepartment of Internal Medicine III, Cardiology and Critical Care, University Hospital Schleswig-Holstein, Kiel, Germany.
Lucia Sophie KilianDepartment of Internal Medicine III, Cardiology and Critical Care, University Hospital Schleswig-Holstein, Kiel, Germany.
Jakob Christoph VoranDepartment of Internal Medicine III, Cardiology and Critical Care, University Hospital Schleswig-Holstein, Kiel, Germany.
Frauke SengerDepartment of Internal Medicine III, Cardiology, University of Heidelberg, Heidelberg, Germany.
Ashraf Yusuf RangrezDepartment of Internal Medicine III, Cardiology, University of Heidelberg, Heidelberg, Germany.
Derk FrankDepartment of Internal Medicine III, Cardiology and Critical Care, University Hospital Schleswig-Holstein, Kiel, Germany.
Christian KuhnDepartment of Internal Medicine III, Cardiology and Critical Care, University Hospital Schleswig-Holstein, Kiel, Germany.
Norbert FreyDepartment of Internal Medicine III, Cardiology, University of Heidelberg, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) are critical post-transcriptional regulators of gene expression and have been extensively implicated in cardiovascular development, homeostasis, and disease. Among them, microRNA-582 (miR-582) has been associated with several non-cardiac pathologies, yet its role in the heart remains poorly characterized despite significant cardiac expression. In this study, we investigated the functional significance of miR-582 in cardiac pathophysiology through both gain- and loss-of-function approaches. We observed differential expression of miR-582 in murine models of cardiomyopathy, prompting further mechanistic evaluation. Thus, we generated transgenic mice with cardiac-specific overexpression of miR-582 (TG-582) as well as miR-582 knockout (582-KO) mice. Neither model exhibited an obvious cardiac phenotype under basal conditions. Following pressure overload via transverse aortic constriction (TAC), both TG-582 and 582-KO mice developed hypertrophy and functional adaptations comparable to wildtype controls. Additionally, crossbreeding these models with Calsarcin-1-knockout (CS1-KO) mice, a model of dilated cardiomyopathy, did not modify the pathological phenotype. These results indicate that miR-582 does not play a determinative role in pressure overload-induced cardiac hypertrophy or in the progression of dilated cardiomyopathy. Our findings highlight the importance of rigorously controlled

Indexed as

Calsarcin-1cardiac hypertrophycardiomyopathyheart failureMicroRNAsmiR-582-5pTransverse aortic constriction (TAC)

Identifiers

PMID41293419
PMCPMC12641005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.